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Predicting treatment response
during the acute phase of
hospitalization
Mary Peterson and William Michael
Objective: This study sought to determine if an initial assessment for an
acute inpatient population was able to predict treatment response as measured
by progress through clinical pathways. In addition, we sought to analyze the
impact of comorbidity on treatment response.
Method: A total of 170 adults (1875 years) admitted for an acute inpatient
hospitalization, received a full assessment including the Brief Symptom
Inventory. Based on assessment results, patients were placed on one of five
clinical pathways. Treatment response was measured by the number of days
spent on each level of the clinical pathway.
Results: Results revealed an unexpected, significant negative correlation
between symptom severity on admission and movement through the clinical
pathway; that is, patients with more severe symptomatic presentations at
assessment made more rapid progress through the clinical pathways. However,
comorbidity showed the strongest relationship with treatment response. Taken
together, these variables explained 52% of the variance in treatment response.
Conclusions: Responsiveness to antipsychotic medications, as well as high
levels of subjective distress and the consequent motivation to achieve relief, may
help explain the unexpected relationship between symptom severity and
treatment response. Findings also demonstrated the utility of an initial
assessment in predicting treatment response.
Key words: assessment, clinical pathways, comorbidity serious mental
illness, treatment response.
A
significant body of research has begun to identify important best
practices in psychosocial rehabilitation for persons with serious
mental illness. The use of assertive community treatment, social
skills training, family involvement, supported employment, and pharma-
cotherapy are among the best practices that predict improved quality of life
and independent functioning for consumers.1 However, there has been less
research regarding effective treatment for persons with serious mental
illness during the acute phase of the illness.
The implementation of clinical pathways in a medical setting provides
evidence-based care using standardized treatment.2 The clinical pathway
attempts to optimize patient care by identifying goals, sequence and
timing of care and staff responsibilities. Developing a comprehensive
clinical pathway requires a collaborative, multidisciplinary effort between
physicians, nurses and relevant adjunct therapists. When the concept of
clinical pathway is applied to psychiatric care, clinicians clarify treatment
interventions and goals in an effort to avoid the use of inefficient therapies
during the typically short length of stay of an acute hospitalization.3
Although clinical pathways have been most commonly used in a general
medical setting, there has been an increase in the development of clinical
Mary Peterson
Assistant Professor, Graduate Department of Clinical
Psychology, George Fox University, Newberg, OR, USA.
William Michael
Medical Director, Behavioral Health Center, Regional West
Medical Center, Two W. 42nd St. Suite 3200, Scottsbluff,
NE 69361, USA.
Correspondence: Dr Mary Peterson, George Fox University,
414 N. Meridian St, Box 6173, Newberg, OR 97132, USA.
Email: mpeterson@georgefox.edu
pathways for the treatment of a variety of psychiatric
conditions including suicidal ideation, eating disor-
ders, anxiety and dementia. Additional benefits in the
use of clinical pathways include shorter length of stay,
cost containment,4 reduction in the variance of care,
and the feedback to staff regarding the effectiveness of
their interventions.5 The link between assessment,
clinical pathway interventions, and outcome has
been less clear. Assessment has been shown to be an
important tool in differential diagnosis, the establish-
ment of a baseline in symptom severity, appropriate
treatment interventions and predicted response to
interventions.6,7 However, we were specifically inter-
ested in determining if there was a link between a
simple, standardized admission assessment and the
outcome of a patient’s progress through the clinical
pathways. We expected to find a positive relationship
between symptom severity on admission and progress
through the clinical pathway; that is, patients with
more severe symptomatology would progress more
slowly through the clinical pathway than patients
with less severe symptomatology.
Research has shown that comorbid personality pathol-
ogy also influences treatment outcome,8 with a num-
ber of studies indicating that the presence of comorbid
Axis I or II diagnoses may negatively affect treatment
outcome.9,10 However, other research has shown that
comorbid conditions had no effect on long-term
relapse rates of patients hospitalized with alcohol
dependency.11 Our second hypothesis was that comor-
bidity would affect treatment outcome; specifically, we
expected that the presence of comorbid psychiatric
conditions would negatively affect progress through
the clinical pathways.
METHOD
Participants
The participants were 170 adult patients, 1875 years
of age, who were admitted for an acute hospital stay.
All patients were assessed for placement on a clinical
pathway after having a comprehensive history, physi-
cal examination, structured clinical interview by the
attending psychiatrist, a complete nursing assessment,
and social history. The Brief Symptom Inventory was
also administered as part of the routine admission
process. After admission data were reviewed, the
attending psychiatrist provided the diagnosis and
ordered clinical pathway assignment. There were
slightly more men than women (57% and 43%,
respectively). The length of stay was 36 days, with
an average length of stay of 4.1 days. Approximately
40% of admissions were involuntary, with the patients
having been placed under emergency protective cus-
tody. The patients’ primary diagnoses included schi-
zoaffective disorder (14%), major depressive disorder
(29%), schizophrenia (18%), bipolar disorder (21%),
and other (18%.). The only persons excluded from the
analysis of the archival data were those patients who
did not meet the criteria for a specific clinical pathway.
In the 10 months of data collection, 22 patients were
not placed on a clinical pathway, and an individua-
lized treatment plan was developed. These patients
were not included in this analysis.
Procedure
On admission, following the intake interview, patients
completed the Brief Symptom Inventory,12 which
assesses nine primary symptom dimensions and three
global indices. The global indices are: (i) a measure of
intensity of distress (PSDI); (ii) a measure of overall
number of symptoms (PST); and (iii) a combined score
including both number of symptoms and intensity of
distress (GSI).
Based on the results of the intake interview, the Brief
Symptom Inventory results and the patients’ clinical
histories, the subjects were placed on one of five
clinical pathways (depression, bipolar, psychosis, sub-
stance abuse or anxiety.) If the patients’ diagnoses did
not match any of the five clinical pathways, indivi-
dualized treatment plans were developed for them and
the patients were not included in the study.
The clinical pathways had three different levels, with
treatment interventions developed for each discipline
including psychiatry, nursing, psychology and recrea-
tional therapy within a multi-disciplinary team.
The patient’s movement through the clinical pathway,
assessed by number of days spent at each level, was
correlated with their intake scores on the global
indices to determine if the initial assessment data
could predict the treatment outcome, measured by
the number of days spent on Level 1 before progressing
to Level 2.
RESULTS
Our results yielded some unexpected findings.
Patients’ scores on the global indices were significantly
correlated with their progress through the clinical
pathways. However, the correlation was negative,
with greater symptom severity at intake (as reported
on the Brief Symptom Inventory) predicting more
rapid progress through the clinical pathways than
less severe symptoms (r(169)//0.327, pB/ 0.001.
The patients who reported the highest level of distress
on admission (as measured by T scores on GSI scale)
actually progressed more quickly through the clinical
pathways (measured by number of days spent at Level
1 before progressing to Level 2, a full day of treatment
programming constituting a treatment day) during the
acute hospitalization stay. In an effort to predict
progression on the clinical pathways, a stepwise
regression analysis was performed with comorbidity
entered as the first variable (b/0.694, pB/ 0.001) and
the GSI score on admission entered as the second
variable (b//0.21, pB/ 0.001). The results of the
regression showed that the strongest predictor of
successful treatment outcome (as measured by move-
ment through the clinical pathways) was comorbidity
(1, 168) R2/0.48 for Step 1, the addition of the GSI
score added to the predictive ability F (2, 167) DR2/
0.04, adjusted R2/0.52, for Step 2, (pB/0.001).
Additional analyses did not reveal a significant rela-
tionship between type of diagnosis and movement
through the clinical pathway (1, 168) R2/0.005.
DISCUSSION
Why would the patients with higher symptom severity
move through the clinical pathways with greater
success than those with fewer or less severe symptoms?
In an attempt to answer that question, we considered
two explanations: responsiveness to antipsychotic
medication and a high subjective level of distress.
Responsiveness to antipsychotic medication
The patients experiencing the most distress endorsed
significantly more severe symptoms, including para-
noia and psychoticism. Severe symptoms of psychosis
often begin to resolve quickly with the initiation of an
appropriate antipsychotic medication and a structured
milieu. One of our staff therapists described the
changes as a ‘transformation’ that occurred during a
typical 4-day stay. The immediate quieting of the most
disturbing symptoms may allow the person to move
successfully through the clinical pathway. In contrast,
if a person’s distress is not as severe, their responsive-
ness may be complicated by a variety of factors,
including personality disorders or substance abuse
problems, which may not have the strong initial
response to treatment.
High subjective level of distress
A second consideration may be that patients have an
increased motivation secondary to a high level of
subjective distress. If individuals are experiencing
significant distress, they may be more motivated to
participate in treatment that will alleviate that distress.
The endorsement of severe symptoms may be their cry
for help, which is answered in part through the milieu
treatment and medication.
Findings concerning comorbidity
The results showed that both comorbidity and symp-
tom severity were significant predictors of treatment
outcome; however, the predictive response was bi-
directional. While high comorbidity predicted a slower
treatment response, high symptom severity predicted a
more rapid treatment response. Comorbidity appeared
to be the more powerful predictor; that is, patients
with high comorbidity and high symptom severity
responded more slowly than patients with high symp-
tom severity and less comorbidity. These results sup-
port earlier research that found comorbid conditions
impact upon treatment response.8,9
Future research may choose to examine long-term
treatment effects to elucidate the relationship between
movement through clinical pathways and symptom
stabilization. Is the initial positive response to treat-
ment predictive of longer periods of stabilization than
a slower response? Some diagnoses may also be more
suited to clinical pathway interventions than others.
Similarly, some comorbid conditions may have a
differential impact on both treatment response and
longer term adjustment. In particular, the powerful
influence of a substance abuse diagnosis, including
chronicity and severity, requires additional research.
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